

TARGETED GENETICS CORP /WA/

Form 8-K

March 18, 2004

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 17, 2004

Targeted Genetics Corporation

(Exact name of registrant as specified in charter)

Washington
(State or other jurisdiction
of incorporation)

0-23930
(Commission
File Number)

91-1549568
(IRS Employer
Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington
(Address of principal executive offices)

98101
(Zip Code)

Registrant's telephone number, including area code (206) 623-7612

Not Applicable

(Former name or former address, if changed since last report)

1

TABLE OF CONTENTS

Item 5. Other Events.

Item 7. Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 5. Other Events.

On March 17, 2004, Targeted Genetics Corporation issued a press release announcing its initiation of a Phase I clinical trial of its product candidate, tgAAC94, in patients with rheumatoid arthritis. A copy of the press release is furnished as Exhibit 99.1 and is incorporated into this current report by reference.

Item 7. Exhibits.

- (a) Financial statements of business acquired.

Not applicable.

- (b) Pro forma financial information.

Not applicable.

- (c) Exhibits.

Exhibit No.	Description
------------------------	--------------------

99.1	Press Release of Targeted Genetics Corporation dated March 17, 2004
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

Date: March 17, 2004

By: /s/ Todd E. Simpson

Todd E. Simpson
Vice President, Finance and Administration
and Chief Financial Officer, Secretary and
Treasurer (Principal Financial and Accounting
Officer)

Table of Contents

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Targeted Genetics Corporation dated March 17, 2004